RBC Capital analyst Gregory Renza reiterated a Sector Perform rating and $24.00 price target on Pacira Pharmaceuticals (NASDAQ: PCRX).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE